⏳ Fetching live dividend data...
Home › Calculator › VYNE Dividend Calculator 2026
VYNE Therapeutics Inc. · NASDAQ
Price: $28.56 · Annual div: $20.12/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in VYNE → $34300042049.65M in 10 years · $2,854,380,252,349,149.00/month
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open VYNE position with:
Real after-tax yield depends on where you live and how you hold VYNE.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 70.45% | 67.65% | $7,045 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 59.88% | 57.08% | $5,988 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 56.36% | 53.56% | $5,636 / yr |
| 🇬🇧 UK ISA | 0% | 70.45% | 67.65% | $7,045 / yr |
| 🇬🇧 UK Taxable | 8.75% | 64.29% | 61.49% | $6,429 / yr |
| 🇨🇦 TFSA | 0% | 70.45% | 67.65% | $7,045 / yr |
| 🇨🇦 CA Taxable | 25% | 52.84% | 50.04% | $5,284 / yr |
| 🇦🇺 Super (pension) | 15% | 59.88% | 57.08% | $5,988 / yr |
| 🇦🇺 AU Taxable | 30% | 49.31% | 46.52% | $4,932 / yr |
| 🇩🇪 DE Taxable | 26.375% | 51.87% | 49.07% | $5,187 / yr |
| 🇫🇷 FR Taxable | 30% | 49.31% | 46.52% | $4,932 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $20.12/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
VYNE pays quarterly — 4 times per year. Next ex-div: TBD.
How VYNE compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for VYNE sourced from FMP /financial-growth endpoint — real data, not estimates.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the VYNE dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
VYNE Therapeutics Inc. (VYNE) is currently trading at $28.56, 100% below its 52-week high. The current dividend yield is 70.45% based on an annual payout of $20.12 per share.
VYNE Therapeutics Inc. (VYNE) is a healthcare stock currently trading at $28.56 with a dividend yield of 70.45%. The company pays an annual dividend of $20.12 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever